1 domain / 2 areas / 1 specialization
Able Partners
Data updated
Able Partners is a New York City-based venture capital firm focused on early-stage consumer companies in health and wellness, with a stated emphasis on improving everyday life and wellbeing. The firm’s team page describes its partners as active investors in early-stage consumer and healthcare businesses, and its public materials frame the firm’s thesis around “positive living” and closing the wellness gap.
In the psychedelic ecosystem, Able Partners is relevant because its public portfolio and investment themes include mental health, substance-use treatment, and companies building around psychedelic-adjacent care delivery. Its website also shows involvement with atai Life Sciences and Compass Pathways, suggesting exposure to the psychedelic mental-health stack alongside broader healthcare and consumer wellness bets.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.
Public Portfolio Examples
- COMPASS PathwaysSeries B - undisclosed - Jan 1, 2020
Able Partners presents as a New York-based early-stage investor that backs companies aimed at improving health, mental wellbeing, and daily living. Its public portfolio orientation spans consumer health and healthcare, with specific interest in stigmatized or underserved categories such as mental health and substance use, which creates a clear fit with psychedelic medicine and adjacent care models. Publicly visible portfolio examples include Compass Pathways, atai Life Sciences, and Journey Clinical, indicating interest across drug development and service infrastructure around mental health innovation.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Recorded Investments
Jan 1, 2020
Series B - undisclosed
Psilocybin-focused mental health biotechnology company; directly relevant to psychedelic drug development.
Mental Health Care Company COMPASS Pathways Concludes Successful Series B Investment RoundQuick Facts
- Founded
- 2013
- HQ
- New York City, New York, United States
- Website
- Visit